Strs Ohio Makes New $2.27 Million Investment in Exelixis, Inc. $EXEL

Strs Ohio bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 61,402 shares of the biotechnology company’s stock, valued at approximately $2,267,000.

Several other institutional investors have also recently added to or reduced their stakes in EXEL. Fuller & Thaler Asset Management Inc. increased its position in Exelixis by 2.2% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 7,795,074 shares of the biotechnology company’s stock worth $287,794,000 after purchasing an additional 164,134 shares during the period. AQR Capital Management LLC boosted its position in Exelixis by 73.8% in the 1st quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock valued at $250,869,000 after buying an additional 2,926,884 shares during the last quarter. Invesco Ltd. lifted its position in shares of Exelixis by 40.2% during the first quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock worth $205,725,000 after purchasing an additional 1,596,948 shares during the last quarter. Nuveen LLC bought a new position in Exelixis in the first quarter worth about $123,310,000. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Exelixis by 2.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 3,321,407 shares of the biotechnology company’s stock valued at $122,626,000 after purchasing an additional 69,054 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Stock Down 0.4%

NASDAQ EXEL opened at $39.01 on Tuesday. The company has a market capitalization of $10.50 billion, a P/E ratio of 18.75, a P/E/G ratio of 0.81 and a beta of 0.32. Exelixis, Inc. has a 12-month low of $25.17 and a 12-month high of $49.62. The firm has a 50-day moving average price of $39.87 and a two-hundred day moving average price of $39.66.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. During the same quarter in the prior year, the firm posted $0.84 EPS. The firm’s quarterly revenue was down 10.8% on a year-over-year basis. Exelixis has set its FY 2025 guidance at EPS. Equities analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on EXEL shares. Morgan Stanley reduced their target price on shares of Exelixis from $48.00 to $46.00 and set an “overweight” rating for the company in a report on Tuesday, July 29th. Zacks Research downgraded shares of Exelixis from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 26th. UBS Group set a $38.00 target price on shares of Exelixis and gave the company a “neutral” rating in a research note on Wednesday, July 30th. Wall Street Zen lowered shares of Exelixis from a “buy” rating to a “hold” rating in a report on Monday. Finally, Benchmark reissued a “neutral” rating on shares of Exelixis in a report on Monday, June 23rd. Thirteen equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $44.06.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.